Arkolith/Insider Trading/RLAY/Form 4

Catinazzo Thomas

Chief Financial OfficerRelay Therapeutics, Inc. (RLAY) · full profile →Form 4 · filed Apr 9, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$257K
Net Open-Market Flow
-$257K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 9, 2026Option exercise(M)2K$5.22$9K216K
Apr 9, 2026Sell(S)2K$15.00$27K214K
Apr 7, 2026Sell(S)18K$13.01$230K214K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 9, 2026Option exercise(M)2K—$062K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-150044) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML